Glucocorticoid replacement is associated with hypertriglyceridaemia, elevated glucose and higher non-HDL cholesterol and may diminish the association of HDL cholesterol with the -629C>A CETP promoter polymorphism in GH-receiving hypopituitary patients

Clinical Endocrinology

Volumn 69, Issue 3, 2008, Pages 359-366

  Dullaart, Robin P F ^a   Schols, Jeroen L ^a   Van Der Steege, Gerrit ^a   Zelissen, Peter M J ^b   Sluiter, Wim J ^a   Van Beek, André P ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL ESTER TRANSFER PROTEIN; CORTISONE ACETATE; GLUCOCORTICOID; HIGH DENSITY LIPOPROTEIN; HUMAN GROWTH HORMONE; HYDROCORTISONE; INSULIN; SULFONYLUREA; TRIACYLGLYCEROL;

ADULT; AGED; ALLELE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORTICOTROPIN DEFICIENCY; DIABETES MELLITUS; DNA POLYMORPHISM; FEMALE; GENETIC VARIABILITY; GLUCOSE BLOOD LEVEL; HOMOZYGOTE; HORMONE SUBSTITUTION; HUMAN; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PITUITARY DWARFISM; PREVALENCE; PRIORITY JOURNAL; SMOKING;

ADOLESCENT; ADULT; AGED; BLOOD GLUCOSE; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEINS; FEMALE; GLUCOCORTICOIDS; HORMONE REPLACEMENT THERAPY; HUMAN GROWTH HORMONE; HUMANS; HYPERTRIGLYCERIDEMIA; HYPOPITUITARISM; LINKAGE (GENETICS); MALE; METABOLIC SYNDROME X; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PREVALENCE; PROMOTER REGIONS, GENETIC; YOUNG ADULT;

EID: 49649084472     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2008.03196.x     Document Type: Article

References (37)

1. Etxabe, J. Vazquez, J.A. (1994) Morbidity and mortality in Cushing's disease: an epidemiological approach. Clinical Endocrinology 40, 479 484.
2. Arnaldi, G., Mancini, T., Polenta, B. Boscaro, M. (2004) Cardiovascular risk in Cushing's syndrome. Pituitary, 7, 253 256.
3. Bergthorsdottir, R., Leonsson-Zachrisson, M., Oden, A. Johannsson, G. (2006) Premature mortality in patients with Addison's disease: a population-based study. Journal of Clinical Endocrinology and Metabolism, 91, 4849 4853.
4. Rosen, T. Bengtsson, B.A. (1990) Premature mortality due to cardiovascular disease in hypopituitarism. Lancet, 336, 285 288.
5. Filipsson, H., Monson, J.P., Koltowska-Haggstrom, M., Mattsson, A. Johannsson, G. (2006) The impact of glucocorticoid replacement regimens on metabolic outcome and comorbidity in hypopituitary patients. Journal of Clinical Endocrinology and Metabolism, 91, 3954 3961.
6. Faggiano, A., Pivonello, R., Spiezia, S., De Martino, M.C., Di Filippella, M., Somma, C., Lombardi, G. Colao, A. (2003) Cardiovascular risk factors and common carotid artery caliber and stiffness in patients with Cushing's disease during active disease and 1 year after disease remission. Journal of Clinical Endocrinology and Metabolism, 88, 2527 2533.
7. Tauchmanova, L., Rossi, R., Biondi, B., Pulcrano, M., Nuzzo, V., Palmieri, E.A., Fazio, S. Lombardi, G. (2002) Patients with subclinical Cushing's syndrome due to adrenal adenoma have increased cardiovascular risk. Journal of Clinical Endocrinology and Metabolism, 87, 4872 4878.
8. Taskinen, M.R., Nikkila, E.A., Pelkonen, R. Sane, T. (1983) Plasma lipoproteins, lipolytic enzymes, and very low density lipoprotein triglyceride turnover in Cushing's syndrome. Journal of Clinical Endocrinology and Metabolism, 57, 619 626.
9. Pivonello, R., Faggiano, A., Lombardi, G. Colao, A. (2005) The metabolic syndrome and cardiovascular risk in Cushing's syndrome. Endocrinology and Metabolism Clinics of North America, 34, 327 339, viii.
10. Abs, R., Feldt-Rasmussen, U., Mattsson, A.F., Monson, J.P., Bengtsson, B.A., Goth, M.I., Wilton, P. Koltowska-Haggstrom, M. (2006) Determinants of cardiovascular risk in 2589 hypopituitary GH-deficient adults - a KIMS database analysis. European Journal of Endocrinology, 155, 79 90.
11. Al-Shoumer, K.A., Cox, K.H., Hughes, C.L., Richmond, W. Johnston, D.G. (1997) Fasting and postprandial lipid abnormalities in hypopituitary women receiving conventional replacement therapy. Journal of Clinical Endocrinology and Metabolism, 82, 2653 2659.
12. Molitch, M.E., Clemmons, D.R., Malozowski, S., Merriam, G.R., Shalet, S.M., Vance, M.L. Stephens, P.A. (2006) Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology and Metabolism, 91, 1621 1634.
13. Friedman, T.C., Mastorakos, G., Newman, T.D., Mullen, N.M., Horton, E.G., Costello, R., Papadopoulos, N.M. Chrousos, G.P. (1996) Carbohydrate and lipid metabolism in endogenous hypercortisolism: shared features with metabolic syndrome X and NIDDM. Endocrine Journal, 43, 645 655.
14. Taskinen, M.R., Kuusi, T., Yki-Jarvinen, H. Nikkila, E.A. (1988) Short-term effects of prednisone on serum lipids and high density lipoprotein subfractions in normolipidemic healthy men. Journal of Clinical Endocrinology and Metabolism, 67, 291 299.
15. Tall, A.R. (1993) Plasma cholesteryl ester transfer protein. Journal of Lipid Research, 34, 1255 1274.
16. Borggreve, S.E., Vries, R. Dullaart, R.P.F. (2003) Alterations in high-density lipoprotein metabolism and reverse cholesterol transport in insulin resistance and type 2 diabetes mellitus: role of lipolytic enzymes, lecithin: cholesterol acyltransferase and lipid transfer proteins. European Journal of Clinical Investigation, 33, 1051 1069.
17. Beentjes, J.A., Van Tol, A., Sluiter, W.J. Dullaart, R.P.F. (2000) Low plasma lecithin: cholesterol acyltransferase and lipid transfer protein activities in growth hormone deficient and acromegalic men: role in altered high density lipoproteins. Atherosclerosis, 153, 491 498.
18. Beentjes, J.A., Van Tol, A., Sluiter, W.J. Dullaart, R.P.F. (2000) Decreased plasma cholesterol esterification and cholesteryl ester transfer in hypopituitary patients on glucocorticoid replacement therapy. Scandinavian Journal of Clinical and Laboratory Investigation, 60, 189 198.
19. Boekholdt, S.M. Thompson, J.F. (2003) Natural genetic variation as a tool in understanding the role of CETP in lipid levels and disease. Journal of Lipid Research, 44, 1080 1093.
20. Boekholdt, S.M., Sacks, F.M., Jukema, J.W., Shepherd, J., Freeman, D.J., McMahon, A.D., Cambien, F., Nicaud, V., de Grooth, G.J., Talmud, P.J., Humphries, S.E., Miller, G.J., Eiriksdottir, G., Gudnason, V., Kauma, H., Kakko, S., Savolainen, M.J., Arca, M., Montali, A., Liu, S., Lanz, H.J., Zwinderman, A.H., Kuivenhoven, J.A. Kastelein, J.J. (2005) Cholesteryl ester transfer protein TaqIB variant, high-density lipoprotein cholesterol levels, cardiovascular risk, and efficacy of pravastatin treatment: individual patient meta-analysis of 13,677 subjects. Circulation, 111, 278 287.
21. Borggreve, S.E., Hillege, H.L., Wolffenbuttel, B.H.R., de Jong, P.E., Bakker, S.J., van der Steege, G., van Tol, A. Dullaart, R.P.F. (2005) The effect of cholesteryl ester transfer protein -629C>A promoter polymorphism on high-density lipoprotein cholesterol is dependent on serum triglycerides. Journal of Clinical Endocrinology and Metabolism, 90, 4198 4204.
22. Dachet, C., Poirier, O., Cambien, F., Chapman, J. Rouis, M. (2000) New functional promoter polymorphism, CETP/-629, in cholesteryl ester transfer protein (CETP) gene related to CETP mass and high density lipoprotein cholesterol levels: role of Sp1/Sp3 in transcriptional regulation. Arteriosclerosis, Thrombosis and Vascular Biology, 20, 507 515.
23. Borggreve, S.E., Hillege, H.L., Wolffenbuttel, B.H.R., de Jong, P.E., Zuurman, M.W., van der Steege, G., Van Tol, A. Dullaart, R.P.F. (2006) An increased coronary risk is paradoxically associated with common cholesteryl ester transfer protein gene variations that relate to higher high-density lipoprotein cholesterol: a population-based study. Journal of Clinical Endocrinology and Metabolism, 91, 3382 3388.
24. Dullaart, R.P.F., Borggreve, S.E., Hillege, H.L. Dallinga-Thie, G. (2007) The association of HDL cholesterol concentration with the -629C>A CETP promoter polymorphism is not fully explained by its relationship with plasma cholesteryl ester transfer. Scandinavian Journal of Clinical and Laboratory Investigation, 68, 99 105.
25. Dullaart, R.P.F., Pasterkamp, S.H., Beentjes, J.A. Sluiter, W.J. (1999) Evaluation of adrenal function in patients with hypothalamic and pituitary disorders: comparison of serum cortisol, urinary free cortisol and the human-corticotrophin releasing hormone test with the insulin tolerance test. Clinical Endocrinology, 50, 465 471.
26. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP 2001) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Journal of the American Medical Association, 285, 2486 2497.
27. Lopez-Virella, M., Stone, P., Ellis, S. Colwell, J. (1977) Cholesterol determination in high-density lipoproteins separated by three different methods. Clinical Chemistry, 23, 882 884.
28. Attanasio, A.F., Lamberts, S.W., Matranga, A.M., Birkett, M.A., Bates, P.C., Valk, N.K., Hilsted, J., Bengtsson, B.A. Strasburger, C.J. (1997) Adult growth hormone (GH)-deficient patients demonstrate heterogeneity between childhood onset and adult onset before and during human GH treatment. Adult Growth Hormone Deficiency Study Group. Journal of Clinical Endocrinology and Metabolism, 82, 82 88.
29. Carroll, P.V., Christ, E.R., Bengtsson, B.A., Carlsson, L., Christiansen, J.S., Clemmons, D., Hintz, R., Ho, K., Laron, Z., Sizonenko, P., Sonksen, P.H., Tanaka, T. Thorne, M. (1998) Growth hormone deficiency in adulthood and the effects of growth hormone replacement: a review. Growth Hormone Research Society Scientific Committee. Journal of Clinical Endocrinology and Metabolism, 83, 382 395.
30. Beentjes, J.A., Van Tol, A., Sluiter, W.J. Dullaart, R.P.F. (2000) Effect of growth hormone replacement therapy on plasma lecithin: cholesterol acyltransferase and lipid transfer protein activities in growth hormone-deficient adults. Journal of Lipid Research, 41, 925 932.
31. Agha, A. Monson, J.P. (2007) Modulation of glucocorticoid metabolism by the growth hormone-IGF-1 axis. Clinical Endocrinology, 66, 459 465.
32. Crown, A. Lightman, S. (2005) Why is the management of glucocorticoid deficiency still controversial: a review of the literature. Clinical Endocrinology, 63, 483 492.
33. Esteban, N.V., Loughlin, T., Yergey, A.L., Zawadzki, J.K., Booth, J.D., Winterer, J.C. Loriaux, D.L. (1991) Daily cortisol production rate in man determined by stable isotope dilution/mass spectrometry. Journal of Clinical Endocrinology and Metabolism, 72, 39 45.
34. Kraan, G.P., Dullaart, R.P.F., Pratt, J.J., Wolthers, B.G., Drayer, N.M. De Bruin, R. (1998) The daily cortisol production reinvestigated in healthy men. The serum and urinary cortisol production rates are not significantly different. Journal of Clinical Endocrinology and Metabolism, 83, 1247 1252.
35. Mah, P.M., Jenkins, R.C., Rostami-Hodjegan, A., Newell-Price, J., Doane, A., Ibbotson, V., Tucker, G.T. Ross, R.J. (2004) Weight-related dosing, timing and monitoring hydrocortisone replacement therapy in patients with adrenal insufficiency. Clinical Endocrinology, 61, 367 375.
36. Carrilho, A.J., Cunha-Neto, M.B., Nunes, V.S., Lottenberg, A.M., Medina, W.L., Nakandakare, E.R., Musolino, N.R., Bronstein, M.D. Quintao, E.C. (2001) Plasma cholesteryl ester transfer protein and lipoprotein levels during treatment of growth hormone-deficient adult humans. Lipids, 36, 549 554.
37. de Vries, R., Perton, F.G., Dallinga-Thie, G., van Roon, A.M., Wolffenbuttel, B.H.R., Van Tol, A. Dullaart, R.P.F. (2005) Plasma cholesteryl ester transfer is a determinant of intima-media thickness in type 2 diabetic and nondiabetic subjects: role of CETP and triglycerides. Diabetes, 54, 3554 3559.